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Abstract. Chronic wounds represent a significant burden to 
health services and are associated with patient morbidity. Novel 
methods to diagnose and/or treat problematic wounds are 
needed. Interleukin (IL)-15 is a cytokine involved in a number 
of biological processes and disease states such as inflammation, 
healing and cancer progression. The current study explores the 
expression profile of IL-15 and IL-15 receptor α (IL-15Rα) in 
chronic wounds and its impact on keratinocytes. IL-15 and 
IL-15Rα expression were examined in healing and non-healing 
chronic wounds using qPCR and immunohistochemical 
analysis. The impact of recombinant IL-15 (rhIL-15) on human 
adult low calcium temperature (HaCaT) keratinocyte growth 
and migratory potential was further examined. IL-15 transcript 
expression was slightly, though non-significantly elevated in 
healing chronic wounds compared with non-healing chronic 
wounds. IL-15 protein staining was minimal in both subtypes 
of chronic wounds. By contrast, IL-15Rα transcript and protein 
expression were both observed to be enhanced in non-healing 
chronic wounds compared with healing chronic wounds. The 
treatment of HaCaT cells with rhIL-15 generally enhanced cell 
growth and promoted migration. Analysis with small molecule 
inhibitors suggested that the pro-migratory effect of rhIL-15 
may be associated with ERK, AKT, PLCγ and FAK signal-
ling. IL-15 may promote healing traits in keratinocytes and 
the differential expression of IL-15Rα is observed in chronic 
wounds. Together, this may imply a complex role for this inter-
leukin in wound healing.
Introduction
The majority of wounds, such as a surgical incision or superfi-
cial injury will heal in an orderly manner within an acceptable 
period of time. In a chronic wound, there is often an underlying 
pathological process, either causing a prolonged injury to 
tissues or greatly impairing normal healing (1). Wounds that 
fail to heal within 3 months are considered chronic and 
3.55/1,000 people in the UK and 3% of those over 60 years of 
age suffer from chronic wounds (2). The prevalence is likely 
to rise with an ageing population. Chronic wounds have a 
major financial impact. The cost to the NHS of frequent nurse 
and doctor appointments, dressings as well as outpatient and 
inpatient treatment complications is significant. The cost of 
chronic wound management in the UK has been estimated to 
be between £2.3 and £3.1 billion annually (3) or 2-3% of the 
NHS budget (4).
The process of repairing tissue after an injury is complex, 
involving overlapping steps. The phases are tightly regulated by 
a plethora of cytokines and growth factors controlling multiple 
cell types to proliferate, differentiate and migrate. Originally, 
4 distinct phases were described. Namely: haemostasis, inflam-
mation, proliferation and maturation or remodelling (5). In an 
acute wound, the phases progress in an orderly and timely 
fashion, with the prompt achievement of healing. Chronic 
wounds can become arrested in one of the above phases of 
healing or the phases progress more slowly than normal. In a 
chronic wound, the complex cascade of cytokines and cellular 
activity is impaired leading to prolonged inflammation, defec-
tive wound matrix and a failure to re-epithelialize. Several 
cytokines have been implicated as having a role in the process 
of wound healing. As inflammation is a key stage in wound 
healing, it is perhaps not surprising that many of these cyto-
kines are known to be regulators of inflammation.
One such pro-inflammatory cytokine is interleukin (IL)-15. 
IL-15 was identified and characterised as a 14-18 kDa protein 
using the simian kidney epithelial cell line CV-1/EBNA (6). 
The data collected from this study allowed for the isolation 
of human IL-15 by specifically probing the human stromal 
cell line IMTLH cDNA library (6). The human IL-15 struc-
ture was defined as a four α-helical bundle cytokine and is 
located on the human chromosome 4q31 (6). IL-15 can exert 
its biological effects using two separate signalling pathways, 
the first of which involves conventional binding and signalling 
via the IL-15 receptor α (IL-15Rα), β and γ chains. IL-15 and 
its family member IL-2 are separate entities with different 
sequence homologies, but there is data to prove significant 
cross-over between IL-15 and the β and γ chains of the IL-2 
receptor (6,7). This then results in the upregulation of natural 
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killer (NK) cell and T-cell activity (6,8,9). Conversely, IL-15 
in mast cells binds to its cognate IL-15RX receptor and does 
not require IL-2 receptor input (9,10). However, the mRNA 
expression of IL-15 in activated T cells is not a significant 
alternative to the large pools of IL-2 present (6). Previous 
findings confirm that IL-15Rα and its juxtracrine-signalling 
ligand IL-15 are present in human adult low calcium tempera-
ture (HaCaT) keratinocytes (11). Previous studies have explored 
IL-15 in wound biology, regeneration and inflammation and 
IL-15 has been demonstrated to promote the proliferation of 
the human keratinocyte HaCaT cell line, through ERK- and 
AKT-dependent pathways and to exert anti-apoptotic effects on 
epidermal keratinocytes (12,13). Other evidence has suggested 
that IL-15 promotes wound healing responses in the liver and 
may enhance regeneration following liver damage (14). A 
study by Kagimoto et al using transgenic IL-15 mouse models, 
has suggested a regulatory role for IL-15 in wound healing 
and mucosal infection, where transgenic IL-15 mice displayed 
accelerated wound healing but enhanced susceptibility to 
genital HSV-2 infection (15). IL-15 has also been implicated 
in a range of inflammatory diseases [reviewed in (16)].
As the clinical field of chronic wounds is such a significant 
burden, new diagnostic markers and potential therapeutic 
targets are needed. This study aims to assess whether IL-15 
has a role in the healing of chronic wounds and to assess its 
effects in vitro on keratinocyte growth and migration.
Materials and methods
Cells and materials. The HaCaT cell line was purchased 
from the German Cancer Research Institute (Heidelberg, 
Germany). Cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM)/Ham's F12 with L-glutamine medium 
(Sigma-Aldrich, Gillingham, UK) supplemented with antibi-
otics (final concentration streptomycin 0.1 mg/ml, penicillin 
100 U/ml, amphotericin 0.25 µg/ml) and 10% foetal calf serum 
(Sigma-Aldrich). Cells were routinely cultured in 25 or 75 cm2 
tissue culture flasks (Greiner Bio-One Ltd., Stonehouse, UK) 
and incubated at 37˚C, 5% CO2 and 95% humidity.
Recombinant IL-15 (rhIL-15) was purchased from Insight 
Biotechnology (Wembley, UK). ERK inhibitor II, AKT 
inhibitor and PLCγ inhibitor (U73122) were purchased from 
Calbiochem (Merck Chemicals Ltd., Nottingham, UK). FAK 
inhibitor was purchased from Tocris (Bristol, UK).
Clinical samples. Biopsies were taken from chronic venous 
leg ulcers in a cohort of 71 patients. The inclusion criteria 
were as follows: no evidence of other diagnosis, no evidence of 
infection and ulcer present for at least 3 months. The samples 
were collected at the wound healing clinic, University Hospital 
of Wales (UHW; Cardiff, UK), after obtaining ethics approval 
from the South East Wales Research Ethics Committee and 
informed written consent from the subjects. The patients were 
treated for 12 weeks with standard treatment. Specifically, this 
consisted of regular wound care with appropriate dressings 
and compression. Compression was produced with 3 layers 
of Tubigrip™ bandages (Mölnlycke Health Care, Dunstable, 
UK) at an appropriate size to deliver 40 mmHg of pressure. 
At the end of the 12 week treatment period, the wounds were 
assessed. The biopsies from those that had decreased in size 
or healed were termed ‘healing’. The biopsies from those that 
had increased in size or had shown no change were termed 
‘non-healing’. The cohort has been described previously (17).
RNA extraction, quantification and reverse transcription. 
RNA was extracted using TRI reagent (Sigma-Aldrich) in 
accordance with the manufacturer's instructions. In brief, 
medium was aspirated from a flask containing a confluent 
monolayer of cells and the cells were lysed in TRI reagent. 
The cell lysate was placed in a 1.8 ml Eppendorf tube and 
incubated at 4˚C for 5 min. Chloroform (0.2 ml) was subse-
quently added and the solution thoroughly shaken for 15 sec 
before standing for 15 min at room temperature. Samples 
were then centrifuged at 12,000 x g for 15 min at 4˚C and 
the upper aqueous phase was removed with a pipette and 
added to an equal volume of isopropanol. This sample was 
incubated at 4˚C for 10 min and then centrifuged at 12,000 x g 
for 10 min to precipitate RNA. The RNA pellet was washed 
twice in 75% ethanol in DEPC water before being dried in a 
drying oven (Techne Hybridiser HB-1D; Wolf Laboratories, 
York, UK) for 10 min at 55˚C. The RNA pellet was dissolved 
in 50-100 µl of DEPC water prior to quantification using an 
Implen nanophotometer (Implen Gmbh, Munich, Germany) 
and standardisation.
Following quantification, standardised amounts of RNA 
were reverse transcribed to generate cDNA using a reverse 
transcription kit (iScript cDNA synthesis kit; Bio-Rad 
Laboratories, Hemel Hempstead, UK). Subsequently, cDNA 
was diluted appropriately and stored at -20˚C until required.
Polymerase chain reaction (PCR). RT-PCR was performed 
using the GoTaq Green master mix (Promega, Madison, WI, 
USA). In each reaction, GoTaq Green master mix, forward 
primer (10 pmol), reverse primer (10 pmol) and nuclease-free 
water were added to cDNA in a 200 µl PCR tube. The primers 
used in this study are detailed in Table I. Primer3 software was 
used to identify primer binding sites and predicted product size. 
The specific cycling conditions were 94˚C for 5 min followed 
by 32-34 cycles of 94˚C for 30 sec, 55˚C for 30 sec and 72˚C for 
40 sec. Following this, a final extension was undertaken at 72˚C 
for 10 min. Following PCR, samples were size separated using 
gel electrophoresis, stained in SYBR Safe (Life Technologies, 
Paisley, UK) and visualised under blue light using a Syngene 
U:Genius 3 system (Geneflow, Lichfield, UK).
Quantitative PCR (qPCR). The Ampliflor UniPrimer Universal 
system (Intergen Co., Purchase, NY, USA) was used to quan-
tify relative transcript copy numbers in each cDNA sample 
as previously described (18). Sample cDNA was combined 
with 2X iQ supermix (Bio-Rad Laboratories), forward primer 
(10 pmol), reverse primer containing the z sequence (1 pmol) 
and a UniPrimer probe (10 pmol). The specific primers are 
outlined in Table I, and the cycling conditions were initial 
denaturing at 94˚C for 5 min followed by 60 cycles of 94˚C for 
10 sec, 55˚C for 15 sec and 72˚C for 20 sec. The incorporation 
and unfolding of the UniPrimer probe, due to its similarity 
to the z sequence, separates a fluorophore from a quencher 
moiety and allows detection of the fluorescent signal which is 
indicative of DNA amplification. Quantification of this signal 
against a standard set of samples allows the quantification of 
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relative transcript copy numbers. Sample quantity was further 
normalised against the GAPDH housekeeping gene levels 
present in the samples.
In vitro growth assay. Cells were seeded into duplicate 96-well 
plates at a density of 3,000 cells/well. Subsequently, the 
same volume of either double concentrate rhIL-15 or normal 
medium was added to the wells to give final concentrations 
of 1, 10, 40 or 100 ng/ml as required. Each 96-well plate 
was incubated at 37˚C with 5% CO2, either overnight or for 
3 days. At the end of the incubation period, the medium was 
aspirated and the cells in each well were fixed in 4% formalde-
hyde (v/v) (Sigma-Aldrich) for 10 min. The formaldehyde was 
then removed and each well was stained with crystal violet 
(0.5% w/v) (Sigma-Aldrich) for 10 min. The crystal violet was 
then washed off with water and re-suspended in 10% acetic 
acid (Sigma-Aldrich) prior to reading absorbance on a plate 
reading spectrophotometer (ELx800; Bio-Tek, Swindon, UK). 
Percentage growth after a 3-day incubation period was calcu-
lated against the overnight plates.
Scratch assay. Cells were grown to confluence in a 24-well 
plate. Following this, the confluent monolayer was scratched 
using a 200 µl pipette tip to generate an artificial wound. 
Subsequently, the media was replaced with either normal media 
or media containing 100 ng/ml rhIL-15 and the wound tracked 
over a 120 min time period under an inverted microscope 
(Leica DMIL LED) on a heated plate at 37˚C (both from Leica 
Microsystems GmbH, Wetzlar, Germany). Images were captured 
every 30 min using a digital camera (Leica DFC3000G; Leica 
Microsystems GmbH) and the distance between the wound 
fronts were calculated using ImageJ software. The distance 
migrated was calculated in comparison to the 0 h wound.
Electric cell-substrate impedance sensing (ECIS). ECIS is 
a novel, real time method used to measure the rate of cells 
repopulating an area from which they have been eliminated 
using electrical wounding (19). This method can be used 
to screen large sample numbers and has been previously 
described (17). In brief, the ECIS Zθ system with 96WE1 
array plates were used (Applied Biophysics Inc., Troy, NY, 
USA). Plates were stabilised prior to the addition of a stan-
dardised number of HaCaT cells and either rhIL-15 treatment 
or control media and incubated at 37˚C. Resistance of the 
cells was monitored by the system and once confluence was 
achieved, the monolayer was wounded electrically (3,000 µA 
for 30 sec/well). Following wounding, the change in resistance 
across the array was monitored and recorded as cells migrated 
back into the wounded area.
Immunohistochemical (IHC) staining. A representative 
subset of tissues from chronic wounds that contained both 
healing (n=12) and non-healing (n=11) wounds was immun-
histochemically analysed using a standard peroxidase 
technique. Briefly, 7 µm frozen sections were firstly fixed 
in dried acetone (Thermo Fisher Scientific, Loughborough, 
UK) for 15 min, air dried for a further 15 min, prior to rehy-
dration in PBS. This was then followed by a permeabilisation 
step where the sections were washed with 0.1% saponin/PBS 
(Sigma-Aldrich) for 30 min. All subsequent washes contained 
0.1% saponin/PBS since this reaction is reversible. The 
sections were then blocked for 1 h with a solution that 
contained 0.1% BSA/0.1% saponin/10% horse serum in PBS. 
All incubations were performed in a humidified box in order 
to prevent the sections from drying. Excess blocking solution 
was then removed and the sections incubated with the rele-
vant primary antibody for 1 h. Two primary antibodies were 
used: anti-IL-15 (sc-8437; ) and anti-IL-15Rα (sc-9172) (both 
from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) 
at a concentration of 1:100 (final concentration 2 µg/ml). 
The sections were then washed with 0.1% saponin/PBS, 
prior to incubation for 30 min with biotinylated secondary 
antibody (Vector Laboratories, Nottingham, UK). Following 
washing, and a further 30 min incubation with the avidin-
biotin complex (ABC) reagent, the final reaction product was 
developed with 3'3-diaminobenzidine solution (5 mg/ml). 
The sections were then washed in tap water, counterstained 
with Gill's hematoxylin (Vector Laboratories), dehydrated, 
cleared in xylene (Thermo Fisher Scientific) and mounted 
in DPX (Merck Chemicals Ltd.). Negative controls were 
performed by omitting the primary antibody and replacing 
it with PBS.
Statistical analysis. The SigmaPlot 11 statistical package was 
used for statistical analysis. Two-sample, two-tailed t-tests, 
Mann-Whitney U test and one or two way ANOVA analysis 
were undertaken depending on data normality. Experimental 
repeats were undertaken for all assays and p<0.05 was consid-
ered to indicate a statistically significant difference.
Results
Expression of IL-15 in clinical samples. The expression 
profile of IL-15 was explored in clinical samples from 





GAPDH (qPCR) AAGGTCATCCATGACAACTT ACTGAACCTGACCGTACAGCCATCCACAGTCTTCTG
ACTGAACCTGACCGTACA represents the z sequence. IL-15, interleukin 15; IL-15Rα, IL-15 receptor α.
JONES et al:  IL-15 IN CHRONIC WOUND HEALING682
chronic wounds using both qPCR transcript analysis and 
IHC staining. Quantitative transcript analysis of the clinical 
samples showed a greater expression of IL-15 mRNA in 
healing wounds (4.058±2.658) compared with non-healing 
wounds (1.458±0.587) (Fig. 1A), though this was not found 
to be statistically significant (p=0.17). Conversely, there was 
a significantly greater expression of IL-15Rα in non-healing 
wounds (0.785±0.45) compared with healing wounds 
(0.0638±0.0638) (p=0.031) (Fig. 2A).
IHC staining for IL-15 was generally negative in 
keratinocytes of all chronic wounds, both healing and 
non-healing (Fig. 1B). Some cells of the inflammatory 
infiltrate directly below the leading migratory wound edge 
showed positive cytoplasmic staining for IL-15. These cells 
had the appearance of macrophages. This was found mostly 
in non-healing wounds (8/11 or 73%) compared with healing 
wounds (2/12 or 17%). IL-15Rα expression was seen in the 
majority of chronic wounds (14/23) (Fig. 2B) with a slightly 
higher number of non-healing wounds expressing IL-15Rα 
compared with healing wounds [8/11 (73%) and 6/12 (50%), 
respectively]. Generally, IL-15Rα expression in the healing 
wounds was nuclear in the basal and lower layers of the 
epidermis, increasing with intensity towards the distal/normal 
tissue (moving away from the wound edge). This staining 
pattern was also seen in the non-healing chronic wounds 
accompanied by cytoplasmic expression in the mature kerati-
nocytes distal to the wound edge.
Impact of IL-15 on HaCaT proliferation. RT-PCR analysis 
indicated that HaCaT cells express both IL-15 and IL-15Rα 
transcripts (Fig. 3A). Expression of the receptor appears to 
be stronger than IL-15, of which two transcript variants were 
Figure 1. Expression profile of interleukin (IL)-15 in chronic wounds. (A) IL-15 transcript expression in healing (n=20) and non-healing (n=51) chronic wounds. 
(B) Immunohistochemical (IHC) analysis of IL-15 protein levels in healing (n=12) and non-healing (n=11) chronic wounds at both wound edge and distal loca-
tions. Minimal expression of IL-15 was observed in wound edge and distal locations of both healing and non-healing chronic wounds. Mean values shown, error 
bars represent SEM, representative images of wound sections shown.
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detected. A recombinant form of IL-15 (rhIL15) was subse-
quently used to explore the effects of this molecule on HaCaT 
cell function. The treatment of HaCaT cells with either 1, 10 
or 100 ng/ml appeared to enhance HaCaT cell growth over a 
3 day incubation, though ANOVA analysis was just outside of 
statistical significance (p=0.07) (Fig. 3B).
IL-15 impacts on HaCaT cell migration. The impact of rhIL-15 
was explored using both ECIS- (Fig. 4A) and conventional 
scratch- (Fig. 4B) based assays. ECIS-based analysis indicated 
a dose-dependent enhancement of HaCaT cell migration 
following treatment with rhIL-15, with the greatest effects 
observed following treatment with 100 ng/ml rhIL-15. The 
effect of this concentration was similarly confirmed using a 
scratch assay methodology. Similar to the findings of the ECIS 
assay, 100 ng/ml rhIL-15 enhanced HaCaT cell migration in 
comparison with the untreated control cells and this effect was 
found to be statistically significant (p<0.001).
To further explore the potential mechanisms responsible for 
the pro-migratory effects of rhIL-15 on HaCaT cells, ECIS assays 
were undertaken using a number of small molecule inhibitors of 
key migratory pathways (Fig. 5). Similar to previous findings, 
treatment with rhIL-15 (40 ng/ml) continued to display a pro-
migratory response in comparison with the untreated cells.
The treatment of HaCaT cells with AKT inhibitor appeared 
to enhance cell migration. Notably, the pro-migratory effects 
observed due to both rhIL-15 or AKT inhibitor alone were 
negated when these compounds were combined (Fig. 5A). 
The addition of a PLCγ inhibitor did not substantially 
impact on the migration rates of HaCaT cells in comparison 
with the untreated controls. However, in combination with 
rhIL-15, PLCγ inhibition negated the pro-migratory effect 
Figure 2. Expression profile of interleukin-15 receptor α (IL-15Rα) in chronic wounds. (A) IL-15Rα transcript expression in healing (n=20) and non-healing 
(n=51) chronic wounds. *p<0.05. (B) Immunohistochemical (IHC) analysis of IL-15Rα protein levels in healing (n=12) and non-healing (n=11) chronic wounds 
at both wound edge and distal locations. In both cases, IL-15Rα expression was enhanced in distal locations compared to wound edge tissue. Mean values 
shown, error bars represent SEM, representative images of wound sections shown.
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of rhIL-15 alone, and also substantially inhibited HaCaT 
cell migration rates in comparison with the untreated control 
cells (Fig. 5B). Similar trends to the AKT inhibitor were 
observed with the addition of FAK inhibitor, which appeared 
to exert pro-migratory effects independently but when added 
in combination with rhIL-15, negated the pro-migratory 
effect of both compounds (Fig. 5C). Finally, the addition of 
ERK inhibitor substantially reduced HaCaT cell migration in 
Figure 3. Expression of interleukin (IL)-15 in human adult low calcium temperature (HaCaT) keratinocytes and impact on HaCaT growth. (A) RT-PCR analysis of 
IL-15 and IL-15 receptor α (IL-15Rα) expression in HaCaT human keratinocytes, -ve control represents no template control. (B) Impact of recombinant IL-15 (rhIL-
15) on HaCaT cell growth at a range of concentrations. Representative images shown. Values represent mean percentage control data. Error bars represent SEM.
Figure 4. Impact of recombinant IL-15 (rhIL-15) on human adult low calcium temperature (HaCaT) cell migration. (A) Electric cell-substrate impedance 
sensing (ECIS)-based analysis demonstrating effects of rhIL-15 on HaCaT cell migration at a range of concentrations. (B) Scratch wound healing assay demon-
strating the impact of 100 ng/ml rhIL-15 on HaCaT cell migration. Representative data shown. Error bars represent standard deviation, ***p<0.001.
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comparison with the untreated control cells and when added 
in combination with rhIL-15, completely abolished the rhIL-15 
pro-migratory effect, demonstrating migratory rates similar to 
those seen with ERK inhibition alone.
Discussion
IL-15 is a cytokine involved in a wide range of biological 
processes and disease states. Given its involvement in inflam-
matory diseases, keratinocyte function and potential to affect 
wound healing, the present study aimed to explore the role of 
this interleukin in chronic wounds.
Quantitative transcript analysis of the clinical samples from 
the chronic wound cohort indicated a greater expression of IL-15 
mRNA in chronic wounds that go on to heal when compared 
with those that do not heal, though this difference was not found 
to be statistically significant. To the best of our knowledge, 
this observation has not been previously documented as most 
studies on IL-15 to date have focused on its role in tumouri-
genesis, particularly in blood-borne tumours including multiple 
myeloma (20), cutaneous T-cell lymphoma (21) and T-cell 
leukaemia (22). IHC staining indicated little IL-15 protein 
expression in the keratinocytes of healing or non-healing 
wounds, with little difference in expression levels observed 
between the healing and non-healing chronic wound samples. 
This discrepancy may be attributed to previous observations 
that IL-15 transcripts are abundantly expressed whereas IL-15 
protein is tightly controlled with expression generally limited 
to monocytes, macrophages and dendritic cells (6,23). This 
is consistent with the IHC observation that IL-15 protein was 
expressed in cells in the inflammatory infiltrate directly below 
the migratory wound edge. The cells in this infiltrate have 
been reported as being predominantly leukocytes and macro-
phages (24). However, this was mostly found in non-healing 
wounds compared with healing wounds, conflicting with the 
qPCR results. Several translational and intracellular protein 
trafficking mechanisms serve to limit the production of IL-15 
protein from the far larger stores of transcript (25). This could 
explain the apparent discrepancy between the mRNA and 
protein expression of IL-15. Somewhat in contrast to this, the 
IL-15Rα receptor was found to be upregulated in non-healing 
chronic wounds compared with healing chronic wounds at both 
transcript and protein levels.
Following on from the clinical data, we explored the 
impact of rhIL-15 on HaCaT keratinocytes and its impact on 
cell growth and migration. The PCR results confirmed that 
IL-15 mRNA and that of IL-15Rα are expressed in HaCaT 
keratinocytes. This is consistent with previous studies of 
IL-15 expression in keratinocytes (11,26). In vitro treatment 
of HaCaT cells with rhIL-15 did not result in statistically 
significant changes to 3 day growth rates, though all treatment 
concentrations displayed a trend of enhanced growth. Previous 
studies have demonstrated a pro-proliferative role for IL-15 in 
HaCaT cells (12) and this interleukin is associated with the 
enhancement of cell proliferation and the inhibition of apop-
tosis in numerous cell lines (11,27-29). One key effect outlined 
in this study was the impact of rhIL-15 on HaCaT cell migra-
tion. Using both ECIS- and scratch assay-based methods, the 
addition of rhIL-15 resulted in an increased rate of HaCaT 
cell migration. Our data indicates that IL-15 is capable of 
enhancing the migratory capacity of HaCaT keratinocytes. 
Similar trends have been seen in other cell types and IL-15 
Figure 5. Impact of pathway inhibitors on recombinant IL-15 (rhIL-15) related migration. Small molecule pathway inhibitors of (A) AKT, (B) PLCγ, (C) FAK 
and (D) ERK were added independently and in conjunction with rhIL-15 to explore potential signalling interactions. Electric cell-substrate impedance 
sensing (ECIS) migration analysis was used, representative data shown.
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has recently been reported to act in a pro-migratory manner on 
the 5637 bladder carcinoma cell line in a wound healing-based 
assay (30). Subsequently, we explored the ability of a number 
of small molecule inhibitors of key pathways to alter the effect 
of rhIL-15 on HaCaT cell migration. A combination of rhIL-15 
with either AKT, FAK, PLCγ or ERK small molecule pathway 
inhibitors was capable of negating the pro-migratory effect 
of rhIL-15, reducing migrational rates to control or below 
control levels. Notably, the combination of rhIL-15 with either 
AKT, FAK or PLCγ inhibitor all appeared to bring about 
migrational rates below that of the individual inhibitor alone, 
suggesting potential links between these pathways and the 
pro-migratory effect of IL-15. IL-15 has previously been shown 
to activate/signal via AKT and ERK1/2 pathways (12,30) and 
the subsequent inhibition of these pathways could negate the 
proliferative role of IL-15 in HaCaT keratinocytes (12) and the 
pro-migratory role of IL-15 in 5637 bladder cancer cells (30). 
The present data implies a possible association between these 
tested pathways and HaCaT cell migration, though further 
research is warranted in order to fully explore this association.
The present study suggests some complex roles for IL-15 
in chronic wound healing. Enhanced IL-15Rα levels are 
observed in non-healing chronic wounds in comparison with 
healing chronic wounds, though treatment of keratinocytes 
with rhIL-15 enhanced pro-healing traits such as growth, 
albeit non-significantly, and migration. Further studies are 
necessary to establish expression profiles in larger wound 
healing cohorts containing normal skin as well as acute and 
chronic wound subtypes.
Acknowledgements
The authors wish to thank the A4B Scheme of the Welsh 
Government Ser Cymru, NRN Life Sciences Research Network 
Wales and Cancer Research Wales for supporting this study.
References
 1. Wright K: Acute and chronic wounds: current managment 
concepts. Clin Nurse Spec 21: 172-173, 2007.
 2. Vowden K, Vowden P and Posnett J: The resource costs of wound 
care in Bradford and Airedale primary care trust in the UK. 
J Wound Care 18: 93-94, 96-98, 100 passim, 2009.
 3. Posnett J and Franks PJ: The burden of chronic wounds in the 
UK. Nurs Times 104: 44-45, 2008.
 4. Drew P, Posnett J, Rusling L and Wound Care Audit T; Wound 
Care Audit Team: The cost of wound care for a local population 
in England. Int Wound J 4: 149-155, 2007.
 5. Schilling JA: Wound healing. Surg Clin North Am 56: 859-874, 
1976.
 6. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, 
Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al: 
Cloning of a T cell growth factor that interacts with the beta 
chain of the interleukin-2 receptor. Science 264: 965-968, 1994.
 7. Giri JG, Anderson DM, Kumaki S, Park LS, Grabstein KH 
and Cosman D: IL-15, a novel T cell growth factor that shares 
activities and receptor components with IL-2. J Leukoc Biol 57: 
763-766, 1995.
 8. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, 
Paxton R, Anderson D, Eisenmann J, Grabstein K and 
Caligiuri MA: Interleukin (IL) 15 is a novel cytokine that 
activates human natural killer cells via components of the IL-2 
receptor. J Exp Med 180: 1395-1403, 1994.
 9. Waldmann TA and Tagaya Y: The multifaceted regulation of 
interleukin-15 expression and the role of this cytokine in NK 
cell differentiation and host response to intracellular pathogens. 
Annu Rev Immunol 17: 19-49, 1999.
10. Tagaya Y, Burton JD, Miyamoto Y and Waldmann TA: 
Identification of a novel receptor/signal transduction pathway for 
IL-15/T in mast cells. EMBO J 15: 4928-4939, 1996.
11. Rückert R, Asadullah K, Seifert M, Budagian VM, Arnold R, 
Trombotto C, Paus R and Bulfone-Paus S: Inhibition of kerati-
nocyte apoptosis by IL-15: a new parameter in the pathogenesis 
of psoriasis? J Immunol 165: 2240-2250, 2000.
12. Yano S, Komine M, Fujimoto M, Okochi H and Tamaki K: 
Interleukin 15 induces the signals of epidermal proliferation through 
ERK and PI 3-kinase in a human epidermal keratinocyte cell line, 
HaCaT. Biochem Biophys Res Commun 301: 841-847, 2003.
13. Lindner G, Rückert R, Bulfone-Paus S and Paus R: Inhibition 
of chemotherapy-induced keratinocyte apoptosis in vivo by 
an interleukin-15-IgG fusion protein. J Invest Dermatol 110: 
457-458, 1998.
14. Suzuki A, McCall S, Choi SS, Sicklick JK, Huang J, Qi Y, 
Zdanowicz M, Camp T, Li YX and Diehl AM: Interleukin-15 
increases hepatic regenerative activity. J Hepatol 45: 410-418, 2006.
15. Kagimoto Y, Yamada H, Ishikawa T, Maeda N, Goshima F, 
Nishiyama Y, Furue M and Yoshikai Y: A regulatory role of 
interleukin 15 in wound healing and mucosal infection in mice. 
J Leukoc Biol 83: 165-172, 2008.
16. McInnes IB and Gracie JA: Interleukin-15: A new cytokine 
target for the treatment of inflammatory diseases. Curr Opin 
Pharmacol 4: 392-397, 2004.
17. Bosanquet DC, Harding KG, Ruge F, Sanders AJ and Jiang WG: 
Expression of IL-24 and IL-24 receptors in human wound tissues 
and the biological implications of IL-24 on keratinocytes. Wound 
Repair Regen 20: 896-903, 2012.
18. Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, 
Ye L and Mansel RE: Eplin-alpha expression in human breast 
cancer, the impact on cellular migration and clinical outcome. 
Mol Cancer 7: 71, 2008.
19. Keese CR, Wegener J, Walker SR and Giaever I: Electrical 
wound-healing assay for cells in vitro. Proc Natl Acad Sci 
USA 101: 1554-1559, 2004.
20. Tinhofer I, Marschitz I, Henn T, Egle A and Greil R: Expression 
of functional interleukin-15 receptor and autocrine production of 
interleukin-15 as mechanisms of tumor propagation in multiple 
myeloma. Blood 95: 610-618, 2000.
21. Leroy S, Dubois S, Tenaud I, Chebassier N, Godard A, Jacques Y 
and Dréno B: Interleukin-15 expression in cutaneous T-cell 
lymphoma (mycosis fungoides and Sézary syndrome). Br J 
Dermatol 144: 1016-1023, 2001.
22. Kukita T, Arima N, Matsushita K, Arimura K, Ohtsubo H, 
Sakaki Y, Fujiwara H, Ozaki A, Matsumoto T and Tei C: 
Autocrine and/or paracrine growth of adult T-cell leukaemia 
tumour cells by interleukin 15. Br J Haematol 119: 467-474, 2002. 
23. Bamford RN, Battiata AP and Waldmann TA: IL-15: the role 
of translational regulation in their expression. J Leukoc Biol 59: 
476-480, 1996.
24. Moore K, Ruge F and Harding KG: T lymphocytes and the lack 
of activated macrophages in wound margin biopsies from chronic 
leg ulcers. Br J Dermatol 137: 188-194, 1997.
25. Kurys G, Tagaya Y, Bamford R, Hanover JA and Waldmann TA: 
The long signal peptide isoform and its alternative processing 
direct the intracellular trafficking of interleukin-15. J Biol 
Chem 275: 30653-30659, 2000.
26. Blauvelt A, Asada H, Klaus-Kovtun V, Altman DJ, Lucey DR 
and Katz SI: Interleukin-15 mRNA is expressed by human 
keratinocytes Langerhans cells, and blood-derived dendritic 
cells and is downregulated by ultraviolet B radiation. J Invest 
Dermatol 106: 1047-1052, 1996.
27. Kuniyasu H, Ohmori H, Sasaki T, Sasahira T, Yoshida K, 
Kitadai Y and Fidler IJ: Production of interleukin 15 by human 
colon cancer cells is associated with induction of mucosal 
hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 9: 
4802-4810, 2003.
28. Shinozaki M, Hirahashi J, Lebedeva T, Liew FY, Salant DJ, 
Maron R and Kelley VR: IL-15, a survival factor for kidney 
epithelial cells, counteracts apoptosis and inflammation during 
nephritis. J Clin Invest 109: 951-960, 2002.
29. Hjorth-Hansen H, Waage A and Börset M: Interleukin-15 blocks 
apoptosis and induces proliferation of the human myeloma cell 
line OH-2 and freshly isolated myeloma cells. Br J Haematol 106: 
28-34, 1999.
30. Park SL, Kim WJ and Moon SK: p21WAF1 mediates the 
IL-15-induced migration and invasion of human bladder 
cancer 5637 cells via the ERK1/2/NF-κB/MMP-9 pathway. Int 
Immunopharmacol 22: 59-65, 2014.
